An FDA advisory committee recommended Thursday that a diabetes drug, liraglutide (Saxenda), be approved for the treatment of obesity.
The Endocrinologic and Metabolic Drugs Advisory Committee voted 14-1 that the benefits of injectable liraglutide, a human GLP-1 analog, outweighed the risks of using the drug.
"This drug seems to have fairly strong evidence of efficacy," said panel member Charles Stanley, MD, of the University of Pennsylvania in Philadelphia. "One of the secondary benefits is risk reduction for diabetes and at least delaying the onset of diabetes, which is very important in these patients."
He added that the company's Risk Evaluation and Mitigation Strategy (REMS) "will be important for monitoring concerns regarding pancreatitis and increased risk of [certain] cancers."
Link to the report on medpage TODAY: http://bit.ly/1oC0Fl0
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen